Piper Jaffray Companies initiated coverage on shares of Stemline Therapeutics (NASDAQ:STML) in a report published on Monday, November 26th, Marketbeat Ratings reports. The firm issued an overweight rating and a $20.00 price target on the biopharmaceutical company’s stock. Piper Jaffray Companies also issued estimates for Stemline Therapeutics’ Q4 2018 earnings at ($0.69) EPS, FY2018 earnings at ($2.76) EPS, Q1 2019 earnings at ($0.67) EPS, Q2 2019 earnings at ($0.53) EPS, Q3 2019 earnings at ($0.36) EPS, Q4 2019 earnings at ($0.33) EPS, FY2019 earnings at ($1.88) EPS, FY2020 earnings at ($0.83) EPS, FY2021 earnings at $0.16 EPS and FY2022 earnings at $0.99 EPS.
STML has been the topic of several other reports. BidaskClub lowered shares of Stemline Therapeutics from a buy rating to a hold rating in a research note on Thursday, November 8th. Zacks Investment Research upgraded shares of Stemline Therapeutics from a sell rating to a hold rating in a research note on Thursday, August 16th. ValuEngine lowered shares of Stemline Therapeutics from a strong-buy rating to a buy rating in a research note on Saturday, November 10th. HC Wainwright set a $38.00 target price on shares of Stemline Therapeutics and gave the stock a buy rating in a research report on Friday, August 10th. Finally, Wedbush restated an outperform rating and set a $22.00 target price on shares of Stemline Therapeutics in a research report on Monday, November 12th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company’s stock. Stemline Therapeutics has an average rating of Buy and a consensus price target of $24.45.
Stemline Therapeutics stock traded down $0.45 during mid-day trading on Monday, hitting $8.23. The company had a trading volume of 2,091,010 shares, compared to its average volume of 470,814. The firm has a market capitalization of $276.03 million, a P/E ratio of -2.80 and a beta of 0.64. Stemline Therapeutics has a 1 year low of $7.82 and a 1 year high of $20.55.
Stemline Therapeutics (NASDAQ:STML) last announced its quarterly earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.73) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.06). As a group, sell-side analysts predict that Stemline Therapeutics will post -2.81 earnings per share for the current year.
In other news, COO Kenneth Hoberman sold 26,296 shares of the firm’s stock in a transaction that occurred on Monday, November 26th. The shares were sold at an average price of $11.85, for a total transaction of $311,607.60. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 14.80% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the company. BlueMountain Capital Management LLC purchased a new position in shares of Stemline Therapeutics during the second quarter worth approximately $137,000. State Board of Administration of Florida Retirement System purchased a new position in shares of Stemline Therapeutics during the second quarter worth approximately $166,000. MetLife Investment Advisors LLC grew its position in shares of Stemline Therapeutics by 54.6% during the third quarter. MetLife Investment Advisors LLC now owns 18,474 shares of the biopharmaceutical company’s stock worth $307,000 after acquiring an additional 6,527 shares during the last quarter. Bank of America Corp DE lifted its holdings in shares of Stemline Therapeutics by 97.8% during the second quarter. Bank of America Corp DE now owns 20,548 shares of the biopharmaceutical company’s stock worth $329,000 after purchasing an additional 10,159 shares during the period. Finally, Algert Global LLC acquired a new stake in shares of Stemline Therapeutics during the second quarter worth $344,000. Institutional investors and hedge funds own 64.20% of the company’s stock.
About Stemline Therapeutics
Stemline Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma.
Featured Story: Do You Need a Fiduciary?
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.